# Terns Pharmaceuticals

Type: Company

Source: GetYourBrief — https://getyourbrief.com/entity/terns-pharmaceuticals
Canonical HTML page: https://getyourbrief.com/entity/terns-pharmaceuticals

## Timeline

- **2028**: Keytruda Patent Expiration — The primary patent for Merck's blockbuster drug Keytruda expires, opening the door for biosimilars.
- **2028**: Keytruda Patent Expiry — Merck faces biosimilar competition for its top-selling immunotherapy drug.
- **2028**: Keytruda Patent Cliff — Merck faces the loss of exclusivity for its top-selling cancer immunotherapy.
- **2028-01-01**: Keytruda Patent Cliff — Expected loss of exclusivity for Merck's top-selling cancer drug, Keytruda.
- **2027**: Pipeline Integration — Merck integrates Terns' small-molecule oncology candidates into its global R&D infrastructure.
- **2027**: TERN-701 Data Readout — Key clinical milestones for the leukemia candidate are expected to drive valuation.
- **2026-Q4**: Expected Closing — Anticipated completion of the acquisition following regulatory and shareholder approvals.
- **2026-08-11**: Argus raises Merck price target — Argus lifts its Merck target from $130 to $145 with a Buy rating, citing pipeline depth and clinical progress.
- **2026-08-11**: Argus raises Merck price target — Argus lifts its Merck target from $130 to $145 with a Buy rating, citing pipeline depth and clinical progress.
- **2026-08-11**: Argus raises Merck price target — Argus lifts its Merck target from $130 to $145 with a Buy rating, citing pipeline depth and clinical progress.
- **2026-08-10**: Merck discloses Evaxion stake — Merck reports holding 1,214,126 shares of Evaxion A/S in a regulatory filing.
- **2026-08-10**: Merck discloses Evaxion stake — Merck reports holding 1,214,126 shares of Evaxion A/S in a regulatory filing.
- **2026-08-10**: Merck discloses Evaxion stake — Merck reports holding 1,214,126 shares of Evaxion A/S in a regulatory filing.
- **2026-Q3**: Expected Closing — The deal is anticipated to close following regulatory approvals and Terns shareholder vote.
- **2026**: Expected Closing — Anticipated completion of the acquisition following regulatory reviews.

## Recent coverage (11 stories, network-wide)

### Merck Takes 1.2M-Share Stake in AI Vaccine Firm Evaxion
2026-08-22 13:50:46 · Sector: health · Sentiment: Positive · Impact: 6/10 · Sources: 2

Merck's disclosure of a 1.21 million-share stake in Evaxion A/S signals growing pharma confidence in AI-discovered vaccine candidates. For health systems, the partnership could accelerate a new class of antigen-targeted vaccines for bacterial pathogens.
Full story: https://gethealthbrief.com/story/merck-stake-evaxion-ai-vaccine-health

### Argus Lifts Merck to $145 After 1.2M Evaxion Stake
2026-08-22 13:50:37 · Sector: finance · Sentiment: Positive · Impact: 6/10 · Sources: 2

Argus raised Merck's price target to $145 on pipeline depth and M&A, while Merck disclosed a small strategic stake in Evaxion. For investors, the story is the huge gap between a mega-cap's $16.6 billion quarter and a micro-cap's cash-burning AI bet.
Full story: https://getfinancebrief.com/story/merck-evaxion-argus-price-target-stake

### Merck's EVX-B3 Option Turns 1.2M Evaxion Stake Into Validation
2026-08-22 13:50:28 · Sector: bio · Sentiment: Positive · Impact: 6/10 · Sources: 2

Merck's option to in-license Evaxion's EVX-B3 vaccine candidate, combined with a 1.21 million-share stake, provides early validation for the biotech's AI antigen discovery platform. For biotech investors, the deal is a discovery-stage bet with long clinical timelines.
Full story: https://getbiobrief.com/story/merck-evaxion-evb3-ai-vaccine-validation

### Merck's 1.21M-Share Stake Backs AI Vaccine Discovery
2026-08-22 13:50:16 · Sector: ai · Sentiment: Positive · Impact: 6/10 · Sources: 2

Merck's stake in Evaxion is a small but meaningful validation that AI can identify viable vaccine antigens. For AI researchers, the EVX-B3 license signals pharma interest in computational biology beyond diagnostics.
Full story: https://getaibrief.com/story/merck-evaxion-ai-vaccine-discovery-validation

### Merck Strikes $6.7B Terns Acquisition to Counter Keytruda Patent Cliff
2026-03-25 19:20:53 · Sector: startups · Sentiment: Positive · Impact: 8/10 · Sources: 2

Merck has agreed to acquire Terns Pharmaceuticals for $6.7 billion, securing a late-stage leukemia candidate to diversify its oncology portfolio. The deal provides Merck with TERN-701, a promising treatment for chronic myeloid leukemia, as it prepares for the 2028 patent expiration of its blockbuster drug Keytruda.
Full story: https://getstartupbrief.com/story/merck-acquires-terns-pharmaceuticals-6-7b

### Merck to Acquire Terns Pharmaceuticals in $6.7B Hematology Push
2026-03-25 19:19:17 · Sector: finance · Sentiment: Positive · Impact: 8/10 · Sources: 2

Merck has entered into a definitive agreement to acquire Terns Pharmaceuticals for $6.7 billion, securing a high-potential leukemia treatment. The deal is a strategic move to diversify Merck's oncology portfolio as it prepares for the 2028 patent expiration of its top-selling drug, Keytruda.
Full story: https://getfinancebrief.com/story/merck-terns-pharmaceuticals-acquisition-leukemia

### Merck to Acquire Terns Pharmaceuticals for $6.7B to Bolster Oncology Pipeline
2026-03-25 19:18:13 · Sector: bio · Sentiment: Positive · Impact: 8/10 · Sources: 2

Merck has entered into a definitive agreement to acquire Terns Pharmaceuticals for $6.7 billion, securing a promising allosteric BCR-ABL inhibitor for leukemia. The deal is a strategic move to diversify Merck's oncology portfolio as it prepares for the 2028 patent expiration of its blockbuster drug, Keytruda.
Full story: https://getbiobrief.com/story/merck-terns-pharmaceuticals-acquisition-6-7b

### Merck Bolsters Oncology Pipeline with $6.7B Acquisition of Terns Pharmaceuticals
2026-03-25 19:17:39 · Sector: health · Sentiment: Positive · Impact: 8/10 · Sources: 2

Merck has reached a definitive agreement to acquire Terns Pharmaceuticals for $6.7 billion, securing a promising Phase 2 leukemia treatment. The cash deal is a strategic move to diversify Merck's oncology portfolio as it prepares for the 2028 patent expiration of its blockbuster drug Keytruda.
Full story: https://gethealthbrief.com/story/merck-acquires-terns-pharmaceuticals-leukemia-deal

### Merck Acquires Terns for $6.7B to Hedge Against Keytruda Patent Cliff
2026-03-25 16:35:43 · Sector: finance · Sentiment: Positive · Impact: 8/10 · Sources: 2

Merck has agreed to acquire Terns Pharmaceuticals for $6.7 billion in cash to bolster its oncology pipeline ahead of the 2028 patent expiration for its blockbuster drug, Keytruda. The deal centers on TERN-701, a promising leukemia treatment that positions Merck to compete directly with established players like Novartis.
Full story: https://getfinancebrief.com/story/merck-terns-acquisition-oncology-pipeline

### Merck to Acquire Terns for $6.7B to Mitigate Keytruda Patent Cliff
2026-03-25 16:35:08 · Sector: bio · Sentiment: Positive · Impact: 8/10 · Sources: 2

Merck has entered into a definitive agreement to acquire Terns Pharmaceuticals for $6.7 billion in cash, a strategic move to diversify its oncology pipeline. The deal centers on Terns' promising leukemia candidate, TERN-701, as Merck prepares for the 2028 patent expiration of its blockbuster immunotherapy, Keytruda.
Full story: https://getbiobrief.com/story/merck-terns-acquisition-oncology-strategy

### Merck to Acquire Terns for $6.7B to Fortify Oncology Pipeline
2026-03-25 16:34:35 · Sector: health · Sentiment: Positive · Impact: 8/10 · Sources: 2

Merck has entered into a definitive agreement to acquire Terns Pharmaceuticals for $6.7 billion, a strategic move designed to diversify its oncology portfolio. The acquisition comes as Merck prepares for the impending patent expiration of its top-selling cancer immunotherapy, Keytruda, later this decade.
Full story: https://gethealthbrief.com/story/merck-terns-acquisition-oncology-strategy

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.